Background: The T1D Exchange Quality Improvement Collaborative (T1DX-QI) is a learning health system of over fifty endocrinology centers working to improve diabetes outcomes through Quality Improvement (QI). Centers join T1DX-QI with varying levels of QI culture and are assigned a QI Coach to support practice transformation. This study summarizes the results of 27 endocrinology centers involved in the T1DX-QI for over 12 months.

Method: Centers completed a 20-question self-assessment survey to measure QI culture over time in four evidence-based areas: QI Team Structure (team roles); QI Foundation (data collection and training); QI Capacity (use of QI tools); and QI Success (scaling up small tests). Data was collected in 2021 and 2022 for the same centers. The overall difference in QI Capacity was calculated using a Chi-Square test.

Results: Overall, QI Culture increased from 67% to 75% from 2021 to 2022 (p-value = 0.005). Figure 1 demonstrates that improvements were seen in three of the four evidence-based areas for both pediatric and adult centers in this time.

Conclusion: Even with as little as one year of involvement with the T1DX-QI, centers experience an improvement in their QI Capacity.


A.Mungmode: None. L.Chao: None. J.Ilkowitz: None. O.Ebekozien: Advisory Panel; Medtronic, Research Support; Eli Lilly and Company, Dexcom, Inc. T1dx-qi collaborative: n/a. O.Odugbesan: None. V.Elisha: None. D.W.Steenkamp: Research Support; Abbott Diabetes, Novo Nordisk. M.K.Kamboj: None. D.Desalvo: Consultant; Dexcom, Inc., Research Support; Insulet Corporation. R.Y.Sonabend: None. A.Neyman: None. P.M.Mathias: None.


The Leona M. and Harry B. Helmsley Charitable Trust

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at